ClinicalTrials.Veeva

Menu

Diagnostic and Prognostic Biomarkers of Sepsis

S

Sohag University

Status

Completed

Conditions

Sepsis

Study type

Observational

Funder types

Other

Identifiers

NCT04767893
Soh-Med-21-02-18

Details and patient eligibility

About

This study aims to evaluate sepsis biomarkers as soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) and soluble urokinase plasminogen activator receptor (sUPAR) in diagnosis of sepsis in comparison to the traditional blood culture and C-reactive protein (CRP) and to evaluate the prognostic value of these biomarkers in comparison to sequential organ failure assessment score (SOFA score), Acute Physiology and Chronic Health Evaluation II ( APACHI score), 28 day mortality.

Full description

Sepsis is usually diagnosed in patients have clinically suspected infections with systemic inflammatory response syndrome (SIRS) manifestations. Patients with SIRS as those with trauma or stroke have the same classic infection signs such as fever and elevated leukocytic count, as long as the microbiological diagnosis is the ultimate diagnostic method, but it has poor sensitivity with delayed results. New biomarkers such as sTREM-1 and sUPAR can be used for rapid diagnosis of sepsis and differentiating it from non infectious inflammatory syndromes. Also these soluble biomarkers can be used for predicting the prognosis of sepsis patients

Enrollment

67 patients

Sex

All

Ages

19 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Temperature of >38oC
  • Heart rate of >90 beats/min
  • Respiratory rate of >20 breaths/min
  • Partial pressure of arterial carbon dioxide (PaCO2) of <32 mmHg
  • White blood cell (WBC) count of >12,000 cells/mm3

Exclusion criteria

  • HIV patients
  • Patients with neutropenia <1000 cells/mm3
  • <18 years of age.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems